Petrelintide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions not publicly disclosed. As an acylated peptide, refrigerated storage (2-8 degrees C) is expected.
Protocol Quick-Reference
Obesity and overweight with comorbidities
Dosing
Amount
Up to 4.8 mg
Frequency
Once weekly
Duration
16 doses (Phase 1b)
Administration
Route
SCSchedule
Once weekly
Timing
Dose escalation protocol used in Phase 1b; ZUPREME Phase 2b trials evaluating optimized dosing
Cycle
Duration
Ongoing (long-term use intended)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (3 tests)
Fasting glucose and HbA1c
When: Baseline
Why: Baseline glycemic status
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk markers
Fasting glucose and HbA1c
When: 12 weeks
Why: Monitor glycemic changes
๐ก Key Considerations
- โInvestigational drug: not approved by any regulatory authority
- โNovel amylin-based mechanism distinct from GLP-1 agonists; may complement GLP-1 therapy
- โClinical data limited to Phase 1b; ZUPREME Phase 2b trials are ongoing
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Weight Management (Phase 1b) | Dose escalation up to 4.8 mg once weekly subcutaneous injection. | Once weekly subcutaneous injection | 16 doses (Phase 1b trial) | The 4.8 mg dose achieved 8.6% body weight loss over 16 once-weekly doses. Well tolerated with no dose-limiting toxicities reported. |
| Weight Management (ZUPREME Phase 2b) | Multiple dose levels under evaluation in ZUPREME-1 (monotherapy) and ZUPREME-2 (combination with GLP-1 agonist). Specific doses not yet disclosed. | Once weekly subcutaneous injection | Phase 2b trial (duration not disclosed) | ZUPREME-1 evaluates petrelintide monotherapy. ZUPREME-2 evaluates combination with a GLP-1 receptor agonist for enhanced weight loss. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Reconstitution details not publicly disclosed. Petrelintide is administered as a once-weekly subcutaneous injection.
Recommended Injection Sites
- โAbdomen
- โThigh
- โUpper arm
๐งStorage Requirements
Storage conditions not publicly disclosed. As an acylated peptide, refrigerated storage (2-8 degrees C) is expected.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Petrelintide is an investigational drug not approved by any regulatory authority. All dosing information is derived from clinical trials.
Phase 1b Dose Escalation#
In Phase 1b, petrelintide was administered as once-weekly subcutaneous injections with dose escalation up to 4.8 mg.
| Dose Level | Weight Loss | Tolerability |
|---|---|---|
| Up to 4.8 mg weekly | 8.6% body weight loss | Well tolerated |
ZUPREME Phase 2b Program#
Two Phase 2b trials are underway:
| Trial | Design | Key Feature |
|---|---|---|
| ZUPREME-1 | Petrelintide monotherapy | Dose-ranging for optimal monotherapy dose |
| ZUPREME-2 | Petrelintide + GLP-1 agonist | Combination for enhanced efficacy |
Administration#
Petrelintide is administered as a once-weekly subcutaneous injection. The combination approach in ZUPREME-2 leverages the complementary mechanisms of amylin and GLP-1 receptor agonism to potentially achieve greater weight loss than either agent alone.
Dosing Context#
Petrelintide belongs to the Metabolic category of research peptides. Dosing protocols for Petrelintide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Petrelintide:
Weight Management (Phase 1b)#
Dose: Dose escalation up to 4.8 mg once weekly subcutaneous injection.
Frequency: Once weekly subcutaneous injection
Duration: 16 doses (Phase 1b trial)
The 4.8 mg dose achieved 8.6% body weight loss over 16 once-weekly doses. Well tolerated with no dose-limiting toxicities reported.
Weight Management (ZUPREME Phase 2b)#
Dose: Multiple dose levels under evaluation in ZUPREME-1 (monotherapy) and ZUPREME-2 (combination with GLP-1 agonist). Specific doses not yet disclosed.
Frequency: Once weekly subcutaneous injection
Duration: Phase 2b trial (duration not disclosed)
ZUPREME-1 evaluates petrelintide monotherapy. ZUPREME-2 evaluates combination with a GLP-1 receptor agonist for enhanced weight loss.
Reconstitution and Preparation#
Reconstitution details not publicly disclosed. Petrelintide is administered as a once-weekly subcutaneous injection.
Injection Sites#
Recommended injection sites for Petrelintide include:
- Abdomen
- Thigh
- Upper arm
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Storage conditions not publicly disclosed. As an acylated peptide, refrigerated storage (2-8 degrees C) is expected.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Petrelintide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.